• Moxifloxacin: Fluoroquinolone Antibiotic for Toxicity & Meta

  2026-07-14

  Moxifloxacin from APExBIO empowers detailed exploration of antibiotic toxicity, cytotoxicity, and metabolic pathways in mammalian cell and animal models. With robust solubility and well-quantified effects on retinal ganglion cells and serum metabolites, it stands out for reproducibility and advanced assay design.

• Tumor-Targeted PAD4 Inhibitors: Mechanisms Blocking NETs in

  2026-07-14

  This study introduces phenylboronic acid (PBA)-modified PAD4 inhibitors with high tumor selectivity, demonstrating their ability to suppress tumor growth and metastasis by specifically disrupting the PAD4-H3cit-NETs pathway in neutrophils. These findings offer a mechanistic advance in cancer therapy by targeting neutrophil extracellular trap formation, with implications for more precise and safer anti-metastatic interventions.

• EdU Imaging Kits (HF594): Technical Guide for Cell Prolifera

  2026-07-13

  EdU Imaging Kits (HF594) enable sensitive and reliable measurement of DNA synthesis during the S-phase, providing a robust alternative to BrdU assays for cell proliferation studies. This product is best suited for researchers needing accurate proliferation quantification in fixed cells via fluorescence microscopy or flow cytometry and is not recommended for live-cell applications or contexts requiring RNA labeling.

• 2'3'-cGAMP (sodium salt): Precision Tool for STING Pathway S

  2026-07-13

  2'3'-cGAMP (sodium salt) from APExBIO sets a gold standard for probing the cGAS-STING pathway, delivering unmatched water solubility and high STING affinity for robust research in innate immunity and immunotherapy. This article details optimized workflows, biological insights, and troubleshooting tactics that empower researchers to exploit this second messenger across cancer, antiviral, and neuroinflammation models.

• Vorinostat for Epigenetic Modulation: Applied Workflows & Ti

  2026-07-12

  Vorinostat (suberoylanilide hydroxamic acid) empowers cancer biology and apoptosis research with reliable, quantifiable HDAC inhibition. This article delivers stepwise protocols, troubleshooting strategies, and case-driven insights—bridging experimental oncology with advanced epigenetic modulation for maximum reproducibility.

• 3-Deazaadenosine Hydrochloride: Precision SAHH Inhibition in

  2026-07-10

  3-Deazaadenosine hydrochloride empowers researchers to dissect methylation-driven mechanisms in hepatic stellate cell activation, offering reproducible and selective control of S-adenosylhomocysteine hydrolase activity. Its versatility and robust solubility profile make it a cornerstone for advanced inflammation and fibrosis research.

• Strategic Advances in STING Pathway Research with 2'3'-cGAMP

  2026-07-09

  Explore the mechanistic and translational frontiers of the cGAS-STING pathway, highlighting how 2'3'-cGAMP (sodium salt) enables high-precision innate immune activation, supports the latest biosensor innovations, and opens new avenues for immunotherapy research. This thought-leadership article draws from recent breakthroughs, including the link between STING activation and D2HG metabolism, offering actionable guidance for translational investigators.

• Calpeptin as a Calpain Inhibitor: Streamlining Fibrosis Rese

  2026-07-09

  Calpeptin, a highly potent calpain inhibitor from APExBIO, empowers researchers to dissect cell death and fibrosis pathways with unparalleled specificity. This article details practical workflows, key troubleshooting strategies, and evidence-driven protocol enhancements for leveraging Calpeptin in advanced pulmonary fibrosis and inflammation studies.

• MDM1 Overexpression Augments p53-Mediated Apoptosis in CRC T

  2026-07-08

  The reference study uncovers that MDM1 overexpression enhances p53 expression and apoptosis in colorectal cancer cells, thereby increasing their sensitivity to chemoradiotherapy. These mechanistic insights position MDM1 as both a functional modulator and a predictive biomarker for treatment response in colorectal cancer.

• Caspase-3–NDUFS1 Axis Drives Trichothecene-Induced Mitochond

  2026-07-08

  This study identifies caspase-3–mediated cleavage of mitochondrial NDUFS1 and ER-localized ERO1α as key drivers of trichothecene-induced reactive oxygen species (ROS) accumulation and hepatotoxicity. The paper provides mechanistic insight into how mitochondrial and ER oxidative stress are linked by a feedback loop, highlighting new potential targets for mitigating mycotoxin toxicity.

• Translational Leverage of CCK-8 Ammonium: Mechanism to Workf

  2026-07-07

  Explore the mechanistic and strategic role of Cholecystokinin octapeptide ammonium (CCK-8 ammonium) in translational research. This article synthesizes primary evidence, protocol strategy, and competitive insights, guiding researchers from molecular actions to actionable workflows with APExBIO's CCK-8 ammonium.

• Monomethyl Auristatin E: Redefining Precision in Translation

  2026-07-07

  Explore how Monomethyl auristatin E (MMAE) is revolutionizing targeted cancer therapy by synergizing its potent antimitotic mechanism with emerging differentiation-based strategies for overcoming cancer cell plasticity. This thought-leadership article provides mechanistic depth, translational insights, and strategic guidance for researchers, highlighting both experimental and clinical advances while positioning APExBIO’s MMAE as an indispensable reagent for next-generation oncology workflows.

• Nintedanib (BIBF 1120): Optimizing Antiangiogenic Cancer Wor

  2026-07-06

  Nintedanib (BIBF 1120) streamlines antiangiogenic and antifibrotic research by enabling precise modulation of VEGFR, PDGFR, and FGFR pathways, particularly excelling in ATRX-deficient cancer models. This guide translates recent breakthroughs and real-world troubleshooting into actionable workflows for advanced oncology and fibrosis studies.

• ZCL278: Strategic Cdc42 Inhibition for Translational Breakth

  2026-07-06

  This thought-leadership article explores the mechanistic and translational relevance of ZCL278, a selective Cdc42 inhibitor, for researchers tackling cell motility, fibrosis, and neurodevelopmental pathways. Anchored by recent advances in Cdc42-targeted anti-fibrotic strategies, it delivers protocol guidance and strategic insight for leveraging ZCL278 as a next-generation tool in complex disease modeling.

• Signal Amplification Strategies: FITC Goat Anti-Rabbit IgG (

  2026-07-05

  This thought-leadership article explores how advanced signal amplification using the FITC Goat Anti-Rabbit IgG (H+L) Antibody from APExBIO is redefining sensitivity and translational rigor in fibrotic disease research. By integrating recent mechanistic breakthroughs on IL-11/GP130 signaling with strategic guidance for immunofluorescence assay design, the article offers translational researchers both a scientific and practical roadmap for rigorous biomarker detection.

16269 records 1/1085 page Next 12345 下5页 Last page